Induction of IL-10 and TGFβ from CD4+CD25+FoxP3+ T Cells Correlates with Parasite Load in Indian Kala-azar Patients Infected with Leishmania donovani

PLoS Neglected Tropical Diseases

Volumn 10, Issue 2, 2016, Pages

  Bhattacharya, Pradyot ^a   Ghosh, Smriti ^a,d   Ejazi, Sarfaraz Ahmad ^a   Rahaman, Mehebubar ^b   Pandey, Krishna ^c   Ravi Das, Vidya Nand ^c   Das, Pradeep ^c   Goswami, Rama Prosad ^b   Saha, Bibhuti ^b   Ali, Nahid ^a  

^a Infectious Diseases and Immunology Divisionn Institute of Chemical Biology   (India)

^b CALCUTTA SCHOOL OF TROPICAL MEDICINE   (India)

^c RAJENDRA MEMORIAL RESEARCH INSTITUTE OF MEDICAL SCIENCES   (India)

^d Serampore College   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GLOBULIN; HEMOGLOBIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 22; MEMBRANE ANTIGEN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; IL10 PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR ALPHA;

ADULT; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; INDIA; LEISHMANIA DONOVANI; LEUKOCYTE COUNT; MALE; PARASITE LOAD; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SPLEEN SIZE; THROMBOCYTE COUNT; VISCERAL LEISHMANIASIS; CASE CONTROL STUDY; ETHNOLOGY; GENETICS; IMMUNOLOGY; PARASITOLOGY; PHYSIOLOGY; YOUNG ADULT;

ADULT; ANTIGENS, CD4; CASE-CONTROL STUDIES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INDIA; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MALE; PARASITE LOAD; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; YOUNG ADULT;

EID: 84959562980     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004422     Document Type: Article

References (60)

1. WHO (2010) Working to overcome the global impact of neglected tropical diseases. First WHO reported on neglected tropical diseases. In WHO Geneva 184.
2. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. 2012;7: e35671. doi: 10.1371/journal.pone.003567122693548
3. Verma S, Kumar R, Katara GK, Singh LC, Negi NS, et al. Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis. PLoS ONE. 2010;5: e10107. doi: 10.1371/journal.pone.001010720404924
4. Gaafar A, Elkadaro AY, Theander TG, Permin H, Ismail A, Kharazmi A, et al. The pathology of cutaneous leishmaniasis due to Leishmania-major in Sudan. Am J Trop Med Hyg. 1995;52: 438–442. 7771611
5. Manson-Bahr PE, Immunity in kala-azar. Trans R Soc Trop Med Hyg. 1961;55: 550–555. 14469435
6. Saha S, Mondal S, Banerjee A, Ghose J, Bhowmick S, Ali N, Immune responses in kala-azar. Indian J Med Res. 2006;123: 245–266. 16778308
7. Carvalho EM, Barral A, Pedralsampaio D, Barralnetto M, Badaro R, Rocha H, et al. Immunological markers of clinical evolution in children recently infected with Leishmania-donovani-chagasi. J Infect Dis. 1992;165: 535–540. 1347057
8. Ghalib HW, Whittle JA, Kubin M, Hashim FA, Elhassan AM, Grabstein KH, et al. IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol. 1995;154: 4623–4629. 7722314
9. Goto H, das Gracas M, Immunoactivation and immunopathogeny during active visceral leishmaniasis. Rev Inst Med Trop Sao Paulo. 2009;51: 241–246. 19893975
10. Nylen S, Sacks D, Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol. 2007;28: 378–384. 17689290
11. Nylen S, Maurya R, Eidsmo L, Das Manandhar K, Sundar S, Sacks D, Splenic accumulation of IL-10 mRNA in T cells distinct from CD4(+) CD25(+) (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med. 2007;204: 805–817. 17389235
12. Sundar S, Reed SG, Sharma S, Mehrotra A, Murray HW, Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg. 1997;56: 522–525. 9180602
13. Babaloo Z, Kaye PM, Eslami MB, Interleukin-13 in Iranian patients with visceral leishmaniasis: relationship to other Th(2) and Th(1) cytokines. Trans R Soc Trop Med Hyg. 2001;95: 85–88. 11280075
14. Kemp M, Kurtzhals JAL, Bendtzen K, Poulsen LK, Hansen MB, Koech DK, et al. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect Immun. 1993;61: 1069–1073. 8432588
15. Ansari NA, Saluja S, Salotra P, Elevated levels of interferon-gamma, interleukin-10, interleukin-6 during active disease in Indian kala azar. Clin Immunol. 2006;119: 339–345. 16540374
16. Khoshdel A, Alborzi A, Rosouli M, Taheri E, Kiany S, Javadian MH, Increased levels of IL-10, IL-12, and IFN-gamma in patients with visceral leishmaniasis. Braz J Infect Dis. 2009;13: 44–46. 19578629
17. Mondal S, Bhattacharya P, Rahaman M, Ali N, Goswami RP, A curative immune profile one week after treatment of indian kala-azar patients predicts success with a short-course liposomal Amphotericin B therapy. PLoS Negl Trop Dis. 2010,4: e764. doi: 10.1371/journal.pntd.000076420668544
18. Karp CL, Elsafi SH, Wynn TA, Satti MMH, Kordofani AM, Hashim FA, et al. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J Clin Investi. 1993;91: 1644–1648.
19. Ghalib HW, Piuvezam MR, Skeiky YAW, Siddig M, Hashim FA, Elhassan AM, et al. Interleukin-10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest. 1993;92: 324–329. 8326000
20. Saha S, Mondal S, Ravindran R, Bhowmick S, Modak D, Mallick S, et al. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J Immunol. 2007;179: 5592–5603. 17911647
21. Kenney RT, Sacks DL, Gam AA, Murray HW, Sundar S, Splenic cytokine responses in Indian kala-azar before and after treatment. J Infect Dis. 1998;177: 815–819. 9498473
22. Caldas A, Favali C, Aquino D, Vinhas V, van Weyenbergh J, Brodskyn C, et al. Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis. BMC Infect Dis. 2005;5: 113. 16364177
23. Ansari NA, Kumar R, Gautam S, Nylen S, Singh OP, Sundar S, et al. IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J Immunol. 2011;186: 3977–3985. doi: 10.4049/jimmunol.100358821357266
24. Singh OP, Gidwani K, Kumar R, Nylen S, Jones SL, Boelaert M, et al. Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood. Clin Vaccine Immunol. 2012;19: 961–966. doi: 10.1128/CVI.00143-1222539471
25. Duarte MIS, de Andrade HF, Jr.Takamura CFH, Sesso A, Tuon FF, TGF-beta and mesenchymal hepatic involvement after visceral leishmaniasis. Parasitol Res. 2009;104: 1129–1136. doi: 10.1007/s00436-008-1298-419057926
26. Frade AF, de Oliveira LC, Costa DL, Nery Costa CH, Aquino D, Van Weyenbergh J, et al. TGFB1 and IL8 gene polymorphisms and susceptibility to visceral leishmaniasis. Infect Genet Evol. 2011;11: 912–916. doi: 10.1016/j.meegid.2011.02.01421376140
27. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL, CD4(+)CD25(+) regulatory T cells control Leishmania major persistence and immunity. Nature. 2002;420: 502–507. 12466842
28. Campanelli AP, Roselino AM, Cavassani KA, Pereira MSF, Mortara RA, Brodskyn CI, et al. CD4(+) CD25(+) T cells in skin lesions of patients with cutaneous leishmaniasis exhibit phenotypic and functional characteristics of natural regulatory T cells. J Infect Dis. 2006;193: 1313–1322. 16586370
29. Salhi A, Rodrigues V, Jr.Santoro F, Dessein H, Romano A, Castellano LR, et al. Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. J Immunol. 2008;180: 6139–6148. 18424735
30. Bahrami F, Darabi H, Riazi-Rad F, Khaze V, Ajdary S, Alimohammadian MH, FOXP3 expression and frequency of regulatory T cells in healed individuals from Leishmania major infection and the asymptomatic cases. Hum Immunol. 2014;75: 1026–1033. doi: 10.1016/j.humimm.2014.08.20425167770
31. Kariminia A, Bourreau E, Pascalis H, Couppie P, Sainte-Marie D, Tacchini-Cottier F, et al. Transforming growth factor beta 1 production by CD4(+) CD25(+) regulatory T cells in peripheral blood mononuclear cells from healthy subjects stimulated with Leishmania guyanensis. Infect Immun. 2005;73: 5908–5914. 16113310
32. Rai AK, Thakur CP, Singh A, Seth T, Srivastava SK, Singh P, et al. Regulatory T cells suppress T cell activation at the pathologic site of human visceral leishmaniasis. PLoS ONE. 2012;7: e31551. doi: 10.1371/journal.pone.003155122347492
33. Bending D, Newland S, Krejci A, Phillips JM, Bray S, Cooke A, et al. Epigenetic changes at Il12rb2 and Tbx21 in relation to plasticity behavior of Th17 cells. J Immunol. 2011;186: 3373–3382. doi: 10.4049/jimmunol.100321621307296
34. Marwaha AK, Leung NJ, McMurchy AN, Levings MK, Th17 cells in autoimmunity and immunodeficiency: protective or pathogenic?Front Immunol. 2012;3: 129. doi: 10.3389/fimmu.2012.0012922675324
35. Boaventura VS, Santos CS, Cardoso CR, de Andrade J, Dos Santos WLC, Clarencio J, et al. Human mucosal leishmaniasis: neutrophils infiltrate areas of tissue damage that express high levels of Th17-related cytokines. Eur J Immunol. 2010;40: 2830–2836. doi: 10.1002/eji.20094011520812234
36. Pitta MGR, Romano A, Cabantous S, Henri S, Hammad A, Kouriba B, et al. IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani. J Clin Invest. 2009;119: 2379–2387. doi: 10.1172/JCI3881319620772
37. Stäger S, Joshi T, Bankoti R, Immune evasive mechanisms contributing to persistent Leishmania donovani infection. Immunol Res. 2010;47: 14–24. doi: 10.1007/s12026-009-8135-420087685
38. Taher JH, Hummadi YMKA-M, Al-Bashir NMT, Al-Araji AS, Lymphocyte phenotyping, using cluster-of-differentiation (CD) markers, in young Iraqi children with visceral leishmaniasis. Ann Trop Med Parasitol. 2009;103: 671–677. doi: 10.1179/000349809X1255410696367220030991
39. Sudarshan M, Weirather JL, Wilson ME, Sundar S, Study of parasite kinetics with antileishmanial drugs using real-time quantitative PCR in Indian visceral leishmaniasis. J Antimicrob Chemother. 2011:66: 1751–1755. doi: 10.1093/jac/dkr18521609983
40. Afrin F, Ali N, Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infect Immun. 1997; 65: 2371–2377. 9169776
41. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ, Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193: 265–275. 14907713
42. Owens BM, Beattie L, Moore JW, Brown N, Mann JL, Dalton JE, et al. IL-10-producing Th1 cells and disease progression are regulated by distinct CD11c⁺ cell populations during visceral leishmaniasis. PLoS Pathog. 2012:8: e1002827. doi: 10.1371/journal.ppat.100282722911108
43. Scholzen A, Mittag D, Rogerson SJ, Cooke BM, Plebanski M, Plasmodium falciparum-mediated induction of human CD25Foxp3 CD4 T cells is independent of direct TCR stimulation and requires IL-2, IL-10 and TGFbeta. PLoS Pathog. 2009:5: e1000543. doi: 10.1371/journal.ppat.100054319680449
44. Lamoreaux L, Roederer M, Koup R, Intracellular cytokine optimization and standard operating procedure. Nat Protoc. 2006;1: 1507–1516. 17406442
45. Brunialti MK, Santos MC, Rigato O, Machado FR, Silva E, Salomao R, Increased percentages of T helper cells producing IL-17 and monocytes expressing markers of alternative activation in patients with sepsis. PLoS One. 2012:7: e37393. doi: 10.1371/journal.pone.003739322693573
46. Nicholson JK, Stein D, Mui T, Mack R, Hubbard M, Denny T, Evaluation of a method for counting absolute numbers of cells with a flow cytometer. Clin Diagn Lab Immunol. 1997:4: 309–313. 9144369
47. Gonzalez-Lombana C, Gimblet C, Bacellar O, Oliveira WW, Passos S, Carvalho LP, et al. IL-17 mediates immunopathology in the absence of IL-10 following Leishmania major infection. PLoS Pathog. 2013;9: e1003243. doi: 10.1371/journal.ppat.100324323555256
48. Sugita S, Kawazoe Y, Imai A, Usui Y, Takahashi M, Mochizuki M, Suppression of IL-22-producing T helper 22 cells by RPE cells via PD-L1/PD-1 interactions. Invest Ophthalmol Vis Sci. 2013;54: 6926–6933. doi: 10.1167/iovs.13-1270324065812
49. Baecher-Allan C, Viglietta V, Hafler DA, Human CD4+CD25+ regulatory T cells. Semin Immunol. 2004;16: 89–97. 15036232
50. el-Safi SH, Hamid N, Omer A, Abdel-Haleem A, Hammad A, Kareem HG, et al. Infection rates with Leishmania donovani and Mycobacterium tuberculosis in a village in eastern Sudan. Trop Med Int Health. 2004;9: 1305–1311. 15598262
51. Santos-Oliveira JR, Regis EG, Leal CR, Cunha RV, Bozza PT, Da-Cruz AM, Evidence that lipopolisaccharide may contribute to the cytokine storm and cellular activation in patients with visceral Leishmaniasis. PLoS Negl Trop Dis. 2011;5: e1198. doi: 10.1371/journal.pntd.000119821765960
52. Endris M, Takele Y, Woldeyohannes D, Tiruneh M, Mohammed R, Moges F, et al. Bacterial sepsis in patients with visceral leishmaniasis in Northwest Ethiopia. Biomed Res Int. 2014;361058.
53. Anderson CF, Lira R, Kamhawi S, Belkaid Y, Wynn TA, Sacks D, IL-10 and TGF-beta control the establishment of persistent and transmissible infections produced by Leishmania tropica in C57BL/6 mice. J. Immunol. 2008;180: 4090–4097. 18322219
54. Gazzinelli RT, Oswald IP, James SL, Sher A, IL-10 inhibits parasite killing and nitrogen-oxide production by IFN-gamma-activated macrophages. J Immunol. 1992;148: 1792–1796. 1541819
55. Alexander J, Brombacher F, (2012) T helper1/t helper2 cells and resistance/susceptibility to leishmania infection: is this paradigm still relevant?Front Immunol. 2012;3: 80. doi: 10.3389/fimmu.2012.0008022566961
56. Duthie MS, Guderian J, Vallur A, Bhatia A, Lima dos Santos P, Vieira de Melo E, et al. Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment. Eur J Clin Microbiol Infect Dis. 2013;33: 639–649. doi: 10.1007/s10096-013-1999-124173820
57. van den Bogaart E, Talha AB, Straetemans M, Mens PF, Adams ER, Grobusch MP, et al. Cytokine profiles amongst Sudanese patients with visceral leishmaniasis and malaria co-infections. BMC Immunol. 2014;15: 16. doi: 10.1186/1471-2172-15-1624886212
58. Kumar R, Nylén S, Immunobiology of visceral leishmaniasis. Front Immunol. 2012;3: 251. doi: 10.3389/fimmu.2012.0025122912637
59. Maurya R, Kumar R, Prajapati VK, Manandhar KD, Sacks D, Sundar S, et al. Human visceral leishmaniasis is not associated with expansion or accumulation of Foxp3+CD4 cells in blood or spleen. Parasite Immunol. 2010;32: 479–483. doi: 10.1111/j.1365-3024.2010.01219.x20591118
60. Katara GK, Ansari NA, Verma S, Ramesh V, Salotra P, Foxp3 and IL-10 expression correlates with parasite burden in lesional tissues of post kala azar dermal leishmaniasis (PKDL) patients. PLoS Negl Trop Dis. 2011;5: e1171. doi: 10.1371/journal.pntd.000117121655313